📊 ARDT Key Takeaways
Is Ardent Health, Inc. (ARDT) a Good Investment?
Ardent Health demonstrates solid financial health with strong liquidity metrics and reasonable leverage, but profitability growth is stalling with net income flat YoY despite 6% revenue growth. The deteriorating EPS (-39.2% YoY) combined with modest net margins (2.1%) and operating margins (4.5%) suggest operational efficiency challenges in a capital-intensive healthcare sector.
Ardent Health shows solid top-line growth, positive net income, and strong operating cash generation, supported by a healthy liquidity position and manageable leverage. However, profitability remains thin for a hospital operator, and the sharp diluted EPS decline despite flat net income suggests weaker per-share earnings quality. The fundamentals are stable but not strong enough to justify a more aggressive rating without clearer margin expansion and sustained earnings growth.
Why Buy Ardent Health, Inc. Stock? ARDT Key Strengths
- Strong liquidity position with 1.97x current ratio and 1.85x quick ratio, providing operational flexibility
- Healthy free cash flow generation of $470.5M (7.4% FCF margin) supporting debt service and potential reinvestment
- Conservative leverage at 0.87x Debt/Equity with $709.6M cash position reducing refinancing risk
- Consistent revenue growth of 6.0% YoY in competitive healthcare market
- Revenue grew 6.0% year over year while remaining profitable
- Operating cash flow of $470.51M and 7.4% FCF margin indicate solid cash generation
- Liquidity is strong with a 1.97x current ratio, 1.85x quick ratio, and $709.60M in cash
ARDT Stock Risks: Ardent Health, Inc. Investment Risks
- Profitability deterioration with flat net income YoY and sharply declining diluted EPS (-39.2%), indicating margin compression or share dilution issues
- Thin net margins of 2.1% and operating margins of 4.5% leave minimal room for operational disruptions or cost pressures
- High capital intensity of healthcare operations with $1.1B long-term debt and relatively low ROA (2.6%) suggesting asset utilization challenges
- Significant increase in insider Form 4 filings (5 in 90 days) warrants monitoring for potential management concerns
- Operating margin of 4.5% and net margin of 2.1% leave limited room for cost pressure or reimbursement shocks
- Diluted EPS fell 39.2% year over year even though net income was flat, pointing to weaker per-share performance
- Debt remains meaningful with $1.12B in long-term debt and 0.87x debt-to-equity
Key Metrics to Watch
- Operating margin trend - whether margin compression reverses or continues with revenue growth
- EPS trajectory - assess if dilution is one-time or structural issue
- Return on Invested Capital - critical for capital-intensive healthcare provider
- Free cash flow sustainability - monitor if FCF can support debt reduction while funding necessary capex
- Operating margin and net margin trend
- Diluted EPS growth versus net income growth
Ardent Health, Inc. (ARDT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Ardent Health, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ARDT Profit Margin, ROE & Profitability Analysis
ARDT vs Healthcare Sector: How Ardent Health, Inc. Compares
How Ardent Health, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ardent Health, Inc. Stock Overvalued? ARDT Valuation Analysis 2026
Based on fundamental analysis, Ardent Health, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ardent Health, Inc. Balance Sheet: ARDT Debt, Cash & Liquidity
ARDT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ardent Health, Inc.'s revenue has shown modest growth of 6% over the 5-year period. The most recent EPS of $0.43 reflects profitable operations.
ARDT Revenue Growth, EPS Growth & YoY Performance
ARDT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.4B | -$23.5M | $-0.17 |
| Q2 2025 | $1.5B | $27.0M | $0.34 |
| Q1 2025 | $1.4B | $27.0M | $0.21 |
| Q3 2024 | $1.4B | $4.1M | $0.17 |
| Q2 2024 | $1.4B | $4.1M | $0.26 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ardent Health, Inc. Dividends, Buybacks & Capital Allocation
ARDT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ardent Health, Inc. (CIK: 0001756655)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ARDT
What is the AI rating for ARDT?
Ardent Health, Inc. (ARDT) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 69% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ARDT's key strengths?
Claude: Strong liquidity position with 1.97x current ratio and 1.85x quick ratio, providing operational flexibility. Healthy free cash flow generation of $470.5M (7.4% FCF margin) supporting debt service and potential reinvestment. ChatGPT: Revenue grew 6.0% year over year while remaining profitable. Operating cash flow of $470.51M and 7.4% FCF margin indicate solid cash generation.
What are the risks of investing in ARDT?
Claude: Profitability deterioration with flat net income YoY and sharply declining diluted EPS (-39.2%), indicating margin compression or share dilution issues. Thin net margins of 2.1% and operating margins of 4.5% leave minimal room for operational disruptions or cost pressures. ChatGPT: Operating margin of 4.5% and net margin of 2.1% leave limited room for cost pressure or reimbursement shocks. Diluted EPS fell 39.2% year over year even though net income was flat, pointing to weaker per-share performance.
What is ARDT's revenue and growth?
Ardent Health, Inc. reported revenue of $6.3B.
Does ARDT pay dividends?
Ardent Health, Inc. does not currently pay dividends.
Where can I find ARDT SEC filings?
Official SEC filings for Ardent Health, Inc. (CIK: 0001756655) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ARDT's EPS?
Ardent Health, Inc. has a diluted EPS of $0.96.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ARDT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ardent Health, Inc. has a HOLD rating with 69% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ARDT stock overvalued or undervalued?
Valuation metrics for ARDT: ROE of 10.5% (sector avg: 15%), net margin of 2.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ARDT stock in 2026?
Our dual AI analysis gives Ardent Health, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ARDT's free cash flow?
Ardent Health, Inc.'s operating cash flow is $470.5M, with capital expenditures of N/A. FCF margin is 7.4%.
How does ARDT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 2.1% (avg: 12%), ROE 10.5% (avg: 15%), current ratio 1.97 (avg: 2).